Microsoft word - rule 1843 2 - classification of drug substances.doc


1843.2. Classification of Drug Substances.

The Board, the board of stewards, the hearing officer, or the administrative law judge, when
adjudicating a hearing for a violation of Business and Professions Code section 19581, shall
consider the classification of the substance as referenced in the California Horse Racing Board
(CHRB) Penalty Categories Listing by Classification (Revised 01/08), hereby incorporated by
reference, which is based on the Association of Racing Commissioners International (ARCI)
Uniform Classification Guidelines for Foreign Substances (4/05), as modified by the Board.
NOTE: Authority cited: Sections 19580, 19581 and 19582, Business and Professions Code.
Reference: Sections 19580, 19581 and 19582, Business and Professions Code.
HISTORY:
1. New rule filed 8-7-95; effective 9-6-95.
2. Amendment filed 12-6-99; effective 12-6-99.
3. Amendment filed 5-23-08; effective 5-23-08

California Horse Racing Board (CHRB)
Penalty Categories
Listing by Classification
Class 1: Stimulant and depressant drugs that have the highest potential to affect performance and that have no generally accepted medical use in the
racing horse. Many of these agents are Drug Enforcement Agency (DEA) schedule II substances. These include the following drugs and their metabolites: Opiates, opium derivatives, synthetic opioids and psychoactive drugs, amphetamines and amphetamine-like drugs as well as related drugs, including but not limited to apmorphine, nikethamide, mazindol, pemoline, and pentylenetetrazol. Trade Name
Drug Class
Trade Name
Drug Class
Penalty Class
Listing by Classification
Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drug Trade
Drug Trade
Listing by Classification
Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drug Trade
Drug Trade
Listing by Classification
Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drug Trade
Drug Trade
Listing by Classification
Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drug Trade
Drug Trade
Listing by Classification
Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drug Trade
Drug Trade
Listing by Classification
Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drug Trade
Drug Trade
Listing by Classification
Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drug Trade
Drug Trade
Valdecoxib
Listing by Classification
Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2. Drug Trade
Drug Trade
Listing by Classification
Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2. Drug Trade
Drug Trade
Listing by Classification
Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2. Drug Trade
Drug Trade
Listing by Classification
Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2. Drug Trade
Penalty Class
metabolite, Trandolaprilat) Trenbolone Finoplix Listing by Classification
Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.
Drug Trade
Drug Trade
Listing by Classification
Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.
Drug Trade
Drug Trade
Listing by Classification
Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.
Drug Trade
Drug Trade
Listing by Classification
Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.
Drug Trade
Drug Trade
Listing by Classification
Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.
Drug Trade
Drug Trade
Listing by Classification
Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.
Drug Trade
Drug Trade
Listing by Classification
Class 5: This class includes the following therapeutic medications for which concentration limits have been established.
Drug Trade
Penalty Class

Source: http://www.losalamitos.com/pdfs/chrb/Rule1843_2_Classification_Drug_Substances.pdf

Maritz announces departure of maritz travel

NEWS RELEASE FOR IMMEDIATE RELEASE For more information, contact: Rick Ryan, Vice President of Business Development(636) 328-6610 DR. JOHN TALLEY HEADLINES NEW MEDICINAL CHEMISTRY PROVIDER Inventor of Celebrex™ serves as chief scientific officer for St. Louis-based SARmont ST. LOUIS (May 25, 2011) – The scientific mind behind pharmaceutical market- changers Celebrex™ and three

tolstoy.newcastle.edu.au

Clinical Chemistry 48:91497–1504 (2002)Limited Sampling Strategy for the Estimation ofMycophenolic Acid Area under the Curve in AdultTomasz Pawinski,1 Mike Hale,2 Magda Korecka,1 William E. Fitzsimmons,3 and Background: Significant relationships between the my- prediction error for the AUC0–12h values not included in cophenolic acid (MPA) area under the concentration– the

Copyright © 2009-2018 Drugs Today